Childhood malignant ovarian germ cell tumors: A monoinstitutional experience

被引:13
作者
Terenziani, M
Massimino, M
Casanova, M
Cefalo, G
Ferrari, A
Luksch, R
Spreafico, F
Polastri, D
Fontanelli, R
Piva, L
Fossati-Bellani, F
机构
[1] Ist Nazl Tumori, Pediat Oncol Unit, I-20133 Milan, Italy
[2] Ist Nazl Tumori, Gynecol Surg Unit, I-20133 Milan, Italy
[3] Ist Nazl Tumori, Urol Unit, I-20133 Milan, Italy
关键词
malignant ovarian germ cell tumors; childhood; iatrogenic sequelae;
D O I
10.1006/gyno.2001.6177
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. We reviewed our 23-year monoinstitutional exprience with childhood malignant ovarian germ cell tumors (MOGCT), with respect to survival and iatrogenic sequelae. Methods. Twenty-nine patients (median age 12 years) with newly diagnosed MOGCT were treated: all girls but 2 underwent surgery as initial treatment. There were 9 pure dysgerminomas and 20 nondysgerminoma tumors (5 immature teratomas, 4 yolk sac tumors, and 11 mixed histology tumors). According to the FIGO classification, 9 girls were classified as stage I, 4 as II, 11 as III, and 3 as IV, and 2 were not evaluable because they were submitted to primary chemotherapy. Twenty-four received chemotherapy with VAC, PVB, or FEB regimens, according to the ongoing protocols through the years. Three stage I girls did not receive adjuvant chemotherapy because of their histology (2 dysgerminomas, 1 immature teratoma) and stage. In the early years, postoperative radiotherapy was given alone in advanced dysgerminoma stages. Results. Five patients died of their disease: 2 dysgerminomas (stage IIIc and IV) and 3 nondysgerminomas (2 stage II and 1 stage IIIc). OS and EFS rates at a median of 112 months were 81.8%. Among 24 survivors, 4 experienced iatrogenic amenorrhea because of radiotherapy andlor bilateral oophorectomy. Conclusions. MOGCT are highly chemosensitive and curable, with preservation of reproductive function. The management of recurrent disease remains an open issue. (C) 2001 Academic Press.
引用
收藏
页码:436 / 440
页数:5
相关论文
共 36 条
[1]  
Abu-Rustum NR, 1998, SEMIN ONCOL, V25, P235
[2]  
[Anonymous], 1986, GYNECOL ONCOL
[3]  
BONAZZI C, 1994, OBSTET GYNECOL, V84, P598
[4]   Outcome and reproductive function after chemotherapy for ovarian dysgerminoma [J].
Brewer, M ;
Gershenson, DM ;
Herzog, CE ;
Mitchell, MF ;
Silva, EG ;
Wharton, JT .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2670-2675
[5]  
Castleberry Robert P., 1997, P921
[6]  
CUSHING B, 1996, P ASCO, V15, pA461
[7]   Surveillance policy for stage I ovarian germ cell tumors [J].
Dark, GG ;
Bower, M ;
Newlands, ES ;
Paradinas, F ;
Rustin, GJS .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :620-624
[8]   NONDYSGERMINOMATOUS TUMORS OF THE OVARY TREATED WITH CISPLATIN, VINBLASTINE, AND BLEOMYCIN - LONG-TERM RESULTS [J].
DEPALO, G ;
ZAMBETTI, M ;
PILOTTI, S ;
ROTTOLI, L ;
SPATTI, G ;
FONTANELLI, R ;
MUSUMECI, R ;
KENDA, R ;
BOMBARDIERI, E ;
STEFANON, B ;
ESCOBEDO, A ;
DELVECCHIO, M ;
DIDONATO, P ;
DIRE, F .
GYNECOLOGIC ONCOLOGY, 1992, 47 (02) :239-246
[9]   CIS-DIAMMINEDICHLOROPLATINUM, VINBLASTINE, AND BLEOMYCIN COMBINATION CHEMOTHERAPY IN DISSEMINATED TESTICULAR CANCER [J].
EINHORN, LH ;
DONOHUE, J .
ANNALS OF INTERNAL MEDICINE, 1977, 87 (03) :293-298
[10]   TREATMENT OF MALIGNANT GERM-CELL TUMORS OF THE OVARY WITH BLEOMYCIN, ETOPOSIDE, AND CISPLATIN [J].
GERSHENSON, DM ;
MORRIS, M ;
CANGIR, A ;
KAVANAGH, JJ ;
STRINGER, CA ;
EDWARDS, CL ;
SILVA, EG ;
WHARTON, JT .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (04) :715-720